FRANKFURT (Reuters) - German drugmaker Bayer said on Friday it requested approval from U.S. regulators for an experimental prostate cancer drug that could eventually generate more than 1 billion euros ($1.31 billion) in annual sales. Radium-223 dichloride, which Bayer used to call Alpharadin, is designed to target bone metastases from prostate cancer that cannot be treated by standard hormone therapy. Bayer licensed radium-223 from Algeta in 2009, and if approved in the United States, radium-223 will be co-promoted by Bayer and Algeta, the Oslo-based company said on Friday. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment